JENA, Germany – January 29, 2026 – InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical firm at the forefront of developing anti-inflammatory treatments by targeting the complement system, today announced its participation in multiple investor conferences during February 2026. Below are the details:
Guggenheim Securities Emerging Outlook: Biotech Summit 2026
February 11–12, 2026 in New York, New York
A fireside chat is scheduled for Wednesday, February 11 at 11:30 AM ET
InflaRx will also host one-on-one investor meetings on February 11th. A link to access the fireside chat live stream and its replay is available .
Oppenheimer 36th Annual Healthcare Life Sciences Conference
February 25–26, 2026 in a virtual format
A virtual presentation will take place on February 25 at 8:40 AM ET
InflaRx will additionally conduct one-on-one investor meetings on February 25th. A link to view the virtual presentation and its replay is available .
About InflaRx
InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics through its proprietary anti-C5a and anti-C5aR technologies, which enable the discovery, development, and commercialization of highly potent, specific inhibitors for the complement activation factor C5a and its receptor, C5aR. C5a is a powerful inflammatory mediator driving progression in a broad range of inflammatory diseases. InflaRx’s lead program is izicopan (INF904), an oral small-molecule inhibitor of C5a-induced signaling via the C5a receptor, which has shown promising PK/PD profiles and therapeutic potential in Phase 1 and Phase 2a clinical trials. The company is advancing izicopan for treating several inflammatory conditions, including hidradenitis suppurativa (HS). It has also developed vilobelimab—a novel, intravenously delivered, first-in-class anti-C5a monoclonal antibody that selectively binds free C5a and demonstrated disease-modifying activity and tolerability across multiple clinical studies.
InflaRx was founded in 2007 and operates offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, Michigan, USA. For more information, please visit . InflaRx GmbH (Germany) and InflaRx Pharmaceuticals Inc. (USA) are fully owned subsidiaries of InflaRx N.V. (collectively, InflaRx).
Contacts:
| InflaRx N.V. | MC Services AG |
| Jan Medina, CFA Vice President, Head of Investor Relations Email: |
Katja Arnold, Laurie Doyle, Dr. Regina Lutz Email: Europe: +49 89-210 2280 U.S.: +1-339-832-0752 |
FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements. All statements not based on historical fact qualify as forward-looking, often marked by terms like “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential,” or “continue,” among others. These statements appear throughout the release and cover our intentions, beliefs, projections, outlook, analyses, current expectations, and the risks, uncertainties, and factors outlined under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in our SEC periodic filings. They reflect the company’s views as of this press release’s date and involve known and unknown risks, uncertainties, and key factors that could cause actual results, performance, or achievements to differ materially from those expressed or implied. Given these variables, you should not place undue reliance on these statements. We assume no obligation to update them in the future, even with new information, except as required by law.
